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Abstract
Background: Angiogenesis is generally involved during the cancer development and hematogenous metastasis.
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are considered to have an
important role in tumor-associated angiogenesis. However, the effects of simultaneously targeting on VEGF and
EGFR on the growth and angiogenesis of colorectal cancer (CRC), and its underlying mechanisms remain unknown.
Methods: Immunohistochemical staining was used to detect the VEGF and EGFR expression in different CRC tissue
specimens, and the correlation between VEGF/EGFR expression with the clinicopathologic features was analyzed. Cell
counting kit‑8 (CCK-8) and transwell assays were used to assess the cellular proliferation and invasion of CRC cells after
treated with anti-VEGF antibody and/or anti-EGFR antibody in vitro, respectively. Moreover, in vivo tumor formation
was performed on nude mice model, and the tumor microvessel density (MVD) was determined by anti-CD34 staining
in different groups. Finally, we evaluated the impact of anti-VEGF antibody and/or anti-EGFR antibody on the activation
of downstream signaling effectors using western blot.
Results: VEGF and EGFR were upregulated in CRC tissues, and their expression levels were correlated with hepatic
metastasis. Blockage on VEGF or EGFR alone could inhibit the cellular proliferation and metastasis while their
combination could reach a good synergism in vitro. In addition, in vivo xenograft mice model demonstrated that the
tumor formation and angiogenesis were strongly suppressed by combination treatment of anti-VEGF and anti-EGFR
antibodies. Besides, the combination treatment significantly reduced the activation of AKT and ERK1/2, but barely
affected the activation of c-Myc, NF-κB/p65 and IκBα in CRC cells tumors. Interestingly, anti-VEGF antibody or anti-EGFR
antibody alone could attenuate the phosphorylation of STAT3 as compared with negative control group, whereas the
combined application not further suppressed but at least partially restored the activation of STAT3 in vivo.
Conclusions: Simultaneous targeting on VEGF and EGFR does show significant inhibition on CRC tumor growth and
angiogenesis in mice model, and these effects are mainly attributed to suppression of the AKT and ERK signaling
pathways.
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Background
Colorectal cancer (CRC) is one of the most common
malignant tumors in the Western World, China, and other
countries [1–3]. The prognosis of CRC at an early stage is
favorable, as a result of improved detection of early cancer
and wider implementation of radical surgery, but the
prognosis of unresectable, advanced CRC is not yet satisfac-
tory. When tumor lesions are not fully resectable or be-
come metastatic, patients will have very limited options for
target agents and conventional chemotherapy. As a result,
the overall outcome of patients is barely satisfied mainly
due to distant metastases formation, especially hepatic and
other hematogenous metastases [4–7], since angiogenesis
and hematogenous metastasis are intrinsically connected.
Thus, countermeasures against tumor angiogenesis seem to
be a promising strategy for improving the prognoses of
these cancer patients.
Angiogenesis, the process leading to the formation of
new blood vessels, plays an important role in tumor devel-
opment and distant metastasis [8], and its induction is
mediated by numerous angiogenic factors [9]. Among
these factors, vascular endothelial growth factor (VEGF)
and its receptors are the most potent molecules activating
endothelial cells metastasis and increasing vascular
permeability [10–12]. Inhibition of VEGF activity has been
reported to suppress the proliferation of cancer cells and
improve the prognosis for unresectable CRC patients [13].
In addition, epidermal growth factor receptor (EGFR),
which plays an important role in tumorigenesis, is over-
expressed in many types of cancers, especially in CRC
[14, 15]. According to the European and US guidelines,
EGFR targeting-therapy has been recommended for the
treatment of metastatic colorectal cancer (mCRC) [12].
However, not all patients have a good response to anti-
EGFR treatment, and there is important clinical value
for identifying predictors of treatment benefit or lack
thereof [16]. Resistance to anti-EGFR therapies is
mediated, at least partly, through activating VEGF-
mediated intracellular cascade [17, 18]. Therefore, a
strategy that simultaneously targets on VEGF and EGFR
agents appears to be promising in preclinical and clinical
studies for the treatment of CRC.
However, very few studies have been conducted to
determine the therapeutic effects of targeting both VEGF
and EGFR for anti-CRC treatment. In this study, we
mainly evaluated the effects of targeting both VEGF and
EGFR on CRC growth and angiogenesis as well as its
relative molecular mechanism using in vitro CRC cell
lines and in vivo mouse model systems.
Methods
Patients and specimens
In this study, a total of 60 CRC tumor tissues and 30
corresponding normal tissues were prepared for
immunohistochemistry assay. Normal tissues were cut at
least 5 cm away from tumor margin. All the specimens
were collected from patients with CRC who were treated
at the Affiliated Hospital of Zunyi Medical University
between May 2015 and December 2015. The study was
conducted in accordance with the 1975 declaration of
Helsinki and with approval from the Ethics Committee
of the Affiliated Hospital of Zunyi Medical University.
Written informed consent was obtained from all partici-
pants. None of the cases received neoadjuvant therapy
before surgery. After surgical resection, the resected
specimens were re-evaluated before the current study by
two pathologists.
Cell lines and culture conditions
The human CRC cell lines HT29, SW480, SW620 and
LoVo were obtained from Cell bank of Chinese Academy
of Sciences (Shanghai, China). All the cancer cells were
cultured in McCoy 5A, RPMI-1640 or Leibovitz’s L-15
medium supplemented with 10 % fetal bovine serum
(FBS) (HyClone, Logan, UT, USA), 100 IU/mL penicillin
and 100 μg/ml streptomycin. All the cells were cultured in
a humidified atmosphere of 5 % CO2 at 37 °C.
Quantitative Real‑time PCR
Total RNA was extracted from cells with Trizol (Invitro-
gen, USA) and reverse transcribed using RT reagent Kit
(TakaRa, Japan) according to the manufacturer’s instruc-
tions. Quantitative reverse transcription-PCR (qRT-PCR)
analysis was performed as previous described [19]. The
sequences of primers in this section are the followings:
(1) VEGF: 5′-CTTGCCTTGCTGCTCTACCT-3′ (for-
ward) and 5′-CTGCATGGTGATGTTGGACT-3′ (re-
verse); (2) EGFR: 5′-GAGAGGAGA ACTGCCAGAA-3′
(forward) and 5′-GTAGCATTTATGGAGAGTG-3′ (re-
verse); (3) GAPDH: 5′-GAAGGTGAAGGTCGGAGTC-
3′ (forward) and 5′-GAAGATGGTGATGGGATTTC-3′
(reverse). GAPDH was used as an internal control.
Western blot analysis
Western blot analysis was performed as previous de-
scribed [19]. The following commercial antibodies were
used in this study: VEGF, EGFR, phospho-c-Myc, total
c-Myc, phospho-NF-κB/p65, total NF-κB/p65, phospho-
IκBα and total IκBα (Abcam, UK), phospho-AKT, total
AKT, phospho-STAT3, total STAT3, phospho-ERK1/2
and total ERK1/2 (Invitrogen, USA), GAPDH and
β-actin (Immunology Consultants Laboratory, USA).
Cell counting kit‑8 assay
The Cell Counting Kit-8 (CCK-8) assay kit (Dojindo,
Kumamoto, Japan) was used to determine the impact of
anti-human VEGF mAb and/or anti-human EGFR mAb
on cell proliferation. The concentrations of anti-VEGF
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or anti-EGFR used in these assays are as following: 0,
0.25, 0.5, 1 and 2 μg/ml. Cells were plated in 96-well
plates at a density of 1 × 104 cells per well for 48 h. 10 μl
CCK-8 solution was added to the cells for 2.5 h at 37 °C,
and the viability of the cells was measured at 450 nm
using an ELISA reader (BioTek, Winooski, VT, USA)
according to the manufacturer’s instructions. For each
experimental condition, 3 wells were used, and the
experiments were repeated 3 times.
Invasion assay
Invasion assays were performed as reported [20]. Trans-
well invasion assays were performed in Corning Matrigel
invasion chamber containing an 8 μm pore-size polycar-
bonate membrane with a uniform layer of BD Matrigel
basement membrane matrix (BD Biosciences, USA).
Three independent experiments were performed with
triplicate wells.
in vivo tumor xenograft model
Female BALB/C nude mice (5–6 weeks old) were used
for xenograft studies. 2 × 106 of control and experimen-
tal cells suspended in phosphate-buffered saline (PBS)
were injected subcutaneously into the right armpit of
mice (six mice each group). Four groups of mice were
tested. Group A was injected with CRC cells (SW620/
LoVo) and non-specific mouse IgG. Group B was
injected with CRC cells and the anti-mouse VEGF mAb
(10 μg), which could react with human and mouse
source VEGF protein. Group C was injected with CRC
cells and the anti-mouse EGFR mAb (10 μg), which
could react with human and mouse source EGFR
protein. Group D was injected with CRC cells and the
anti-mouse VEGF mAb (10 μg) and anti-mouse EGFR
mAb (10 μg). Tumor volume was determined by exter-
nal measurement according to the formula (d2 × D)/2
[21]. Mice were sacrificed after 35 days, and tumors
were harvested, weighted and examined histologically.
Immunohistochemical studies
Immunohistochemical assay for paraffin-embedded
tissues were performed as reported [19, 20]. The evalu-
ation principle was quantified based on the immunore-
active score (IRS), which was calculated as a product of
staining intensity (SI) and percentage of positive cells
(PP). SI is determined as follows: no staining (score 0),
light yellow (score 1), buffy (score 2) and brown (score
3). PP is determined as follows: less than 5 % (score 0),
6 %–25 % (score 1), 26 %–50 % (score 2), 51 %–75 %
(score 3) and >76 % (score 4). By multiplying SI and PP,
the final weighed expression score was ranged from 0 to
12. Five random fields in each section were selected for
the evaluation. The sections scoring at least 3 points in
our study were indicating positive protein expression.
Quantification of microvessel density
Tumor MVD was determined as described [22]. The
slides were examined under × 100 magnication to iden-
tify the highest vascular density area within the tumor,
and one field magnified 200-fold in each of five vascular-
ized areas was counted. The average of the five areas
was recorded as the MVD level of this case. Any brown-
staining endothelial cell or endothelial cell cluster that
was clearly separate from adjacent microvessels, tumor
cells, and other connective tissue elements was consid-
ered as a single, countable microvessel.
IL6 ELISA
Supernatants collected from CRC cell xenografts were
assayed by the IL6 ELISA Kit (Invitrogen) according to
the manufacturer’s instructions. Experiments were per-
formed in duplicates.
Statistical analysis
All values were represented as the mean ± SEM from at
least three independent experiments. Clinical correlative
studies were performed by Pearson’s χ2-test using
SPSS19.0 software system. Student’s t-test for two
groups or one-way analysis of variance (ANOVA) for
three or more groups were performed to evaluate the
statistical significance by using GraphPad Prism 5
software. P values less than 0.05 were considered statisti-
cally significant.
Results
Clinical significance of VEGF/EGFR expression in CRC
tissues
It has been widely recognized that VEGF and EGFR are
overexpressed in CRC tissues. In this study, we also
detected the expression of VEGF and EGFR in different
colorectal tissues. The VEGF and EGFR expression levels
were evidently higher in liver-metastatic CRC samples
than that in non-metastatic CRC samples or noncancer-
ous samples (Fig. 1a and b). The VEGF and EGFR expres-
sion levels in non-metastatic CRC tissues were also higher
than that in normal tissues (Fig. 1a and b). In addition, the
results of immunohistochemical staining showed that
positive signals of VEGF and EGFR were mainly occurred
in the cell membrane and cytoplasm (Fig. 1c).
To further identify the clinical importance of VEGF/
EGFR in CRC, we analyzed the correlationship between
the VEGF/EGFR protein level with clinicopathological
characteristics, including age, gender, tumor size, hist-
ology, tumor location, differentiation status, hepatic me-
tastasis and TNM stage. Strikingly, VEGF expression
was evidently correlated with tumor size, hepatic metas-
tasis and TNM stage (Table 1). However, no relationship
was found between the VEGF expression and other clini-
copathological characteristics including age, gender,
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histology, tumor location and differentiation status
(Table 1). In addition, EGFR expression was evidently
correlated with tumor size, differentiation status, hepatic
metastasis and TNM stage (Table 1). However, no
relationship was found between the EGFR expression
and other clinicopathological characteristics including
age, gender, histology, and tumor location (Table 1).
Taken together, these data strongly indicated that VEGF
and EGFR were positively correlated with the metastasis
of CRC.
VEGF/EGFR expression in CRC cell lines
Furthermore, we detected the VEGF/EGFR expression in
CRC cell lines and found that VEGF/EGFR expression in
the highly invasive CRC cell lines (SW620 and LoVo)
were evidently up-regulated than those in the minimally
metastatic CRC cell lines (SW480 and HT29) (Fig. 2).
Effects of combination anti-VEGF mAb and anti-EGFR
mAb on CRC cells growth and invasion in vitro
In order to confirm the role of anti-VEGF mAb (mono-
clonal antibody) or anti-EGFR mAb on CRC cells
growth in vitro, SW620 and LoVo cells were treated
with different concentrations of anti-VEGF mAb or
anti-EGFR mAb. Cell counting kit‑8 (CCK-8) assay kit
was used to detect proliferation activity of these cells.
The results showed that anti-VEGF mAb or anti-EGFR
mAb could independently prohibit the cell proliferation
in a concentration dependent manner (Additional file 1:
Figure S1). Considered facilitately observed the experi-
mental results, we chose moderate anti-VEGF mAb or
anti-EGFR mAb concentration (0.5 μg/ml) to explore
the proliferation and invasion of CRC cells in vitro. As
shown in Fig. 3a, the proliferation of SW620/LoVo cells
was obviously inhibited in the presence of both
anti-VEGF mAb and anti-EGFR mAb, compared with
Fig. 1 VEGF and EGFR expression are significantly upregulated in liver-metastatic CRC tissues. a Results of VEGF staining were evaluated by the
staining scores. b Results of EGFR staining were evaluated by the staining scores. c Immunohistochemistry analysis of VEGF and EGFR expression
in different colorectal tissues. *P < 0.05
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the presence of anti-VEGF mAb or anti-EGFR mAb
alone. Transwell assay identified that the invasion of
SW620/LoVo cells was suppressed in the presence of
anti-VEGF mAb or anti-EGFR mAb alone, compared
with negative control group (Fig. 3b and c). When both
anti-VEGF mAb and anti-EGFR mAb were present, the
mobility of these cells was further reduced (Fig. 3b and
c). These results revealed that both anti-VEGF mAb and
anti-EGFR mAb could suppress growth and metastasis
of CRC cells in culture.
Effect of anti-VEGF mAb and anti-EGFR mAb on CRC cells
tumorigenicity in vivo
Cultured SW620 cells were subcutaneously injected in
mice, and tumor formation was observed 35 days after
injection (Fig. 4a). In addition, tumor weight was mea-
sured in these groups. As a result (Fig. 4b), the average
tumor weight of SW620 cells in the presence of both
anti-VEGF mAb and anti-EGFR mAb was 0.198 ±
0.022 g, which was significantly lower (P < 0.05) than
that of mice inoculated with anti-VEGF mAb (0.412 ±
0.036 g), anti-EGFR mAb (0.440 ± 0.038 g), and negative
control group (0.952 ± 0.056 g). When LoVo cells were
injected with non-specific mouse IgG, the average tumor
weight was 1.134 ± 0.083 g. It was 0.462 ± 0.062 g in the
presence of anti-VEGF mAb, 0.506 ± 0.059 g in the
presence of anti-EGFR mAb, and 0.244 ± 0.025 g in the
presence of both anti-VEGF and anti-EGFR antibodies
(Fig. 4b). These results suggested that both anti-VEGF
mAb and anti-EGFR mAb could inhibit CRC cells
tumorigenicity in vivo.
Suppression of tumor angiogenesis by CRC cells after
application of anti-VEGF mAb and anti-EGFR mAb
Accordingly, the amount of microvessel density (MVD)
determined using anti-CD34 mAb immunostaining in
the same mouse tumors (Fig. 5a and b). The number of
positive cells in SW620 tumors with non-specific mouse
IgG was 49.00 ± 3.22 per field-of-view, 27.00 ± 3.46,
30.33 ± 3.18 per field-of-view in the presence of anti-
VEGF mAb or anti-EGFR mAb, and 12.67 ± 2.96 in the
presence of both antibodies. In the LoVo tumors, there
Table 1 Clinicopathologic factors and VEGF/EGFR expression in 60 CRC patients
Characteristics Total
(N)
VEGF expression P-value EGFR expression P-value
Positive Negative Positive Negative
Age (years) 0.832 0.406
> 60 34 24 10 29 5
≤ 60 26 19 7 20 6
Gender 0.761 0.128
Male 37 26 11 28 9
Female 23 17 6 21 2
Tumor size (cm) 0.043* 0.018*
> 5 40 32 8 36 4
≤ 5 20 11 9 13 7
Histology 0.950 0.827
Tubular 42 30 12 34 8
Mucinous/Papillary 18 13 5 15 3
Tumor location 0.890 0.982
Colon 22 16 6 18 4
Rectal 38 27 11 31 7
Differentiation status 0.101 0.027*
Well/Moderate 44 29 15 33 11
Poor 16 14 2 16 0
Hepatic metastasis 0.005* 0.034*
Absent 45 28 17 34 11
Present 15 15 0 15 0
TNM stage 0.037* 0.012*
I-II 41 26 15 30 11
III-IV 19 17 2 19 0
Note: *P < 0.05
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were 53.00 ± 3.46 positive cells per field-of-view in
negative control group. 25.00 ± 2.89, 30.33 ± 3.93 cells
were observed in the presence of anti-VEGF mAb or
anti-EGFR mAb, and 14.00 ± 3.79 cells were observed in
the presence of both antibodies (Fig. 5b). These results
indicated that both anti-VEGF and anti-EGFR antibodies
could reduce tumor angiogenesis.
The activity of VEGF and EGFR-dependent signaling in
CRC cells tumors after application of anti-VEGF and anti-
EGFR antibodies
As both VEGF and EGFR can activate phosphatidylinositol
3-kinase (PI3K), mitogen activated protein kinase (MAPK)
and janus kinase (JAK) signaling pathways [23–26], we
examined the downstream effectors, AKT, extracellular
signal-regulated kinase (ERK) and signal transducer and
activator of transcription 3 (STAT3), respectively. As
expected, VEGF or EGFR inhibition by mAb downregu-
lated the phosphorylation of AKT, ERK1/2 and STAT3 as
compared with negative control group (Fig. 6a, b and
Additional file 2: Figure S2A, B). In addition, the
phosphorylation of AKT and ERK1/2 was further
reduced in the presence of both anti-VEGF mAb and
anti-EGFR mAb as compared with anti-VEGF mAb or
anti-EGFR mAb alone (Fig. 6a, b and Additional file 2:
Figure S2A, B). Unfortunately, when combined treat-
ment with anti-EGFR and anti-VEGF antibodies, the
phosphorylation of STAT3 was not further suppressed,
but at least, partially restored (Fig. 6a, b and Additional
file 2: Figure S2A, B). It has been widely recognized
that STAT3 signaling pathway links inflammation to
cell transformation, and STAT3 activation is dependent
on IL6 levels [27]. To explore whether IL6 expression
associates with the activation of STAT3 signaling, we
detected the expression of IL6 in the same mouse
tumors. The levels of IL6 were slightly decreased in the
presence of anti-VEGF mAb or anti-EGFR mAb alone,
compared with negative control group. However, when
both anti-VEGF mAb and anti-EGFR mAb were
present, IL6 levels were significantly up-regulated in
CRC cell tumors (Additional file 3: Figure S3). These
results suggested that anti-VEGF and anti-EGFR anti-
bodies could attenuate PI3K and ERK signaling, but not
IL6/STAT3 signaling in CRC cell tumors.
Notably, other signaling effectors, such as c-Myc
oncogene [28] and nuclear factor kappa B (NF-κB) [29]
are frequently reported to involve in the development of
many types of tumors. In addition, IκBα functions as an
inhibitor of NF-κB, which interacts with p65 to form an
inactive NF-κB/IκBα complex, and then inhibits the
activation of NF-κB signaling pathway [30, 31]. In order
to determine whether anti-VEGF and anti-EGFR
antibodies could suppress the activation of these signal-
ing effectors, we examined the expression of c-Myc,
Fig. 2 Expression of VEGF and EGFR in CRC cell lines. a Expression of VEGF in four human CRC cell lines was detected by qRT-PCR. b Expression
of EGFR in four human CRC cell lines was detected by qRT-PCR. c Western blot analysis of VEGF and EGFR expression in different CRC cell lines
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Fig. 3 (See legend on next page.)
Ding et al. BMC Cancer  (2016) 16:791 Page 7 of 13
(See figure on previous page.)
Fig. 3 Combined application of anti-VEGF and anti-EGFR antibodies suppresses the proliferation and invasion of CRC cells in vitro. a The proliferation rate
of SW620 and LoVo cells were analyzed by CCK-8 assay in different groups. b Invasion assay of SW620 and LoVo cells in different groups. c Invasion of
SW620 and LoVo cells were quantitatively analyzed in different groups. Columns are the average of three independent experiments ± SEM.
*P< 0.05; **P< 0.01
Fig. 4 Suppression of CRC cells tumorigenicity by anti-VEGF and anti-EGFR antibodies in vivo. a Representative photographs of tumor formation
in mice in response to SW620 cells. b Five weeks later, the tumors were resected and weighted. The weight analyzed with Student’s t-test. Data
represent means ± SEM. *P < 0.05
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NF-κB/p65 and IκBα in CRC cell tumors by western
blot. We found that the activation of phospho-c-Myc,
phospho-NF-κB/p65 and phospho-IκBα was not marked
increased or decreased in the presence of anti-VEGF
antibody or anti-EGFR antibody compared with the con-
trol group (Fig. 6c, d and Additional file 2: Figure S2C,
D). Moreover, when both anti-VEGF and anti-EGFR
antibodies were present, there were also no significant
differences in the activation of these factors (Fig. 6c, d
and Additional file 2: Figure S2C, D). Taken together,
these findings indicated that anti-VEGF and anti-EGFR
antibodies couldn’t sufficient to inhibiting the activation
of c-Myc and NF-κB.
Discussion
It has been demonstrated that overexpression of VEGF/
EGFR is correlated with the progression and metastasis
of CRC [32–34]. Despite that previous studies found the
suppressing role of anti-VEGF/EGFR antibody on CRC
development [35, 36], the potential effect of combination
anti-VEGF and anti-EGFR antibodies on CRC growth
and angiogenesis remains little known. In this study, we
have shown that both increased VEGF and EGFR were
associated with hepatic metastases in CRC. Additionally,
we found that anti-VEGF and EGFR antibodies could
not only reduce CRC cells proliferation and invasion in
vitro, but also inhibit the tumor growth and angiogenesis
in vivo mainly through prohibiting the activation of
AKT and ERK signaling pathways. However, monoclonal
antibodies targeting VEGF and EGFR may be un-
sufficient to controlling the activity of other signaling
pathways such as IL6/STAT3 signaling, which may ex-
emplify the underlying mechanism of anti-tumor
resistance.
Animal studies have manifested that inhibition of
VEGF suppresses both tumor angiogenesis and tumor
growth in vivo [37, 38]. Preclinical and clinical studies
also suggest that inhibition of VEGF pathway causes direct
and rapid changes to the tumor vasculature, and improves
the overall survival rate of mCRC patients [39, 40]. In
addition, there is accumulating evidence suggesting that
before the selection of anti-VEGF agents, anti-EGFR agents
deliver their maximum efficacy in mCRC patients when
given early in the treatment strategy [41]. Of note, many
studies have indicated that EGFR has a potent effect on
tumor-associated angiogenesis and combined treatment
with anti-EGFR and anti-VEGF antibodies have at least
additive antitumor activity [42, 43]. Importantly, clinical
Fig. 5 Suppression of CRC cells tumor angiogenesis by anti-VEGF and anti-EGFR antibodies. a Representative photographs of anti-CD34 staining
in SW620 cells tumors. b The numbers of positively CD34 stained cells in subcutaneous SW620 and LoVo cells tumors. The data are representative
of at least three different experiments ± SEM. *P < 0.05
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trials have also produced promising data: combining the
anti-VEGF monoclonal antibody bevacizumab with the
anti-EGFR antibody cetuximab or the EGFR tyrosine kinase
inhibitor erlotinib increases benefit compared with either of
these anti-EGFR agents alone or combined with chemo-
therapy [44]. In this study, we found that the proliferation
and invasion of CRC cells were obviously inhibited in the
presence of both anti-VEGF and anti-EGFR antibodies in
culture. Furthermore, when anti-EGFR combined with
anti-VEGF treatment, the tumor growth and angiogenesis
were significantly suppressed compared with other groups.
These findings provided new evidence supporting the
collaboration of anti-VEGF and anti-EGFR antibodies in
inhibiting tumor growth and angiogenesis.
Fig. 6 Combined application of anti-VEGF and anti-EGFR antibodies attenuates the activation of AKT and ERK, but not STAT3, c-Myc and NF-κB in
vivo. a Western blot analysis was performed to determine the activation of AKT, ERK1/2 and STAT3 in different SW620 cells tumors. b Western blot
assay of different LoVo cells tumors (one clone, a). c Western blot analysis was performed to determine the activation of c-Myc, NF-κB/p65 and
IκBα in different SW620 cells tumors. d Western blot assay of different LoVo cells tumors (one clone, c)
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The mitogen-activated extracellular signal-regulated
kinase (MEK)/ERK and PI3K/AKT signaling pathways
are often concurrently activated in CRC, which are asso-
ciated with the progression, metastasis and drug resist-
ance of CRC [45–47]. VEGF and EGFR are known to
function as two upstream effectors of the PI3K and
MAPK pathways [23, 24]. In this study, we demonstrated
that anti-VEGF antibody cooperated with anti-EGFR
antibody in suppressing the phosphorylation of AKT and
ERK1/2 in nude mouse model. In addition, STAT3 is
persistently activated in many human cancers during
cancer development and progression [48]. Interestingly,
we found that anti-VEGF antibody or anti-EGFR anti-
body alone could attenuate the activation of STAT3, but
simultaneous targeting of both VEGF and EGFR partially
restored the phosphorylation of STAT3 in vivo. Al-
though VEGF and EGFR can activate JAK/STAT3 signal-
ing pathway, a variety of extracellular stimuli especially
IL6 expression, is necessary for the activation of STAT3
signaling [25–27]. Hence, we detected the expression of
IL6 in CRC cell tumors, and found that the trend of IL6
levels were consistent with that of STAT3 activation in the
same tumors. One plausible explanation is that when anti-
VEGF mAb or anti-EGFR mAb alone inhibits tumor
growth, it also slightly decreases the expression of IL6
because of destruction of some tumor cells, while anti-
VEGF and anti-EGFR antibodies simultaneously suppress
tumorigenesis, the surviving tumor cells increase IL6
levels to escape the killing effect. Of note, it has been
widely recognized that inhibition of JAK/STAT3 signaling
is participated in chemotherapeutic sensitivity of CRC
patients [49, 50]. These data suggested that combined
application of anti-VEGF and anti-EGFR antibodies could
sufficient suppress the activation of AKT and ERK signal-
ing, but not IL6/STAT3 signaling pathway, and may
indicate the underlying mechanism of chemotherapeutic
resistance.
Of further interest, we examined the impact of both
anti-VEGF and anti-EGFR antibodies on the activation
of c-Myc and NF-κB in CRC cell tumors. Unfortunately,
we found no significant differences between the phos-
phorylation of c-Myc, NF-κB/p65, IκBα, and the applica-
tion of anti-VEGF antibody and/or anti-EGFR antibody
in vivo. Despite that previous studies suggested the
enigmatic regulation mechanisms of c-Myc and NF-κB
activation, the role of activated c-Myc and NF-κB in
tumor drug resistance is very affirmative [51, 52]. Of
note, persistent activation of STAT3 signaling promotes
uncontrolled growth and survival through dysregulation
of gene expression including c-Myc, and thereby
contributes to oncogenesis [53]. In addition, constitutive
and persistent NF-κB activation in cancer cells is partly
dependent on STAT3 status [54]. These findings and our
results implied a plausible hypothesis that the invalid
effect of both anti-VEGF and anti-EGFR antibodies on
the activity of c-Myc and NF-κB is partly attributed to
the STAT3 status.
Progression-free and overall survival in patients with
mCRC was improved greatly by the addition of anti-
VEGF and/or anti-EGFR to standard chemotherapy, in
either first- or second-line treatment. [12, 55]. However,
several clinical results have suggested that VEGF and
EGFR combinatory therapy do not improve the overall
prognosis in CRC [56]. In the present work, we convin-
cingly showed that simultaneous targeting of both VEGF
and EGFR could further suppress the proliferation and
invasion of CRC cells in vitro, and further inhibit CRC
cell tumor growth and angiogenesis through downregu-
lation of AKT and ERK signaling in vivo. Although our
data is not in line with clinical results, the STAT3 status,
at least, may partly explain the inefficiencies of VEGF/
EGFR co-inhibition in clinical trial.
Conclusions
In conclusion, this study demonstrates that combined
application of anti-VEGF and anti-EGFR antibodies could
inhibit CRC growth and angiogenesis mainly by suppress-
ing AKT and ERK signaling pathways in mice model.
However, other molecular targets including STAT3, c-
Myc and NF-κB may contribute to enhance the risk of
drug-resistance to chemotherapy targeting VEGF and
EGFR.
Additional files
Additional file 1: Figure S1. Effect of different anti-VEGF mAb or
anti-EGFR mAb concentration on the proliferation of SW620 and LoVo
cells in vitro. A The proliferation rate of SW620 and LoVo cells were
analyzed by CCK-8 assay in different anti-VEGF mAb concentration.
B The proliferation rate of SW620 and LoVo cells were analyzed by CCK-8
assay in different anti-EGFR mAb concentration. (TIF 1121 kb)
Additional file 2: Figure S2. Combined application of anti-VEGF and
anti-EGFR antibodies inhibits AKT and ERK signaling pathways in mice model.
A The expression of p-AKT, p-ERK1/2 and p-STAT3 were quantitatively
analyzed in different SW620 cells tumors. B Western blot assay of different
LoVo cells tumors (one clone, A). C The expression of p-c-Myc, p-NF-κB/p65
and p-IκBα were quantitatively analyzed in different SW620 cells tumors.
D Western blot assay of different LoVo cells tumors (one clone, C).
The data are representative of at least three different experiments ±
SEM. *P < 0.05 (TIF 1285 kb)
Additional file 3: Figure S3. The levels of IL6 in CRC cell tumors.
A The expression of IL6 was quantitatively analyzed in different SW620
cells tumors. B ELISA assay of different LoVo cells tumors (one clone, A).
The data are representative of at least three different experiments ±
SEM. NS: No statistical significance; *P < 0.05 (TIF 1783 kb)
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